Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets (Details)

v3.10.0.1
Intangible Assets (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Intangible Assets [Line Items]        
Balance     $ 6,477  
Amortization $ (208) $ (256) (669) $ (409)
Impairment 0 $ 0 (653) $ 0
Balance 5,155   5,155  
Gross asset value 7,513   7,513  
Accumulated Amortization (2,358)   (2,358)  
Balance 5,155   5,155  
Bertilimumab iCo [Member]        
Intangible Assets [Line Items]        
Balance     1,419  
Amortization     (126)  
Impairment     0  
Balance 1,293   1,293  
Gross asset value 2,509   2,509  
Accumulated Amortization (1,216)   (1,216)  
Balance 1,293   1,293  
NanomAbs Yissum [Member]        
Intangible Assets [Line Items]        
Balance     383  
Amortization     (36)  
Impairment     0  
Balance 347   347  
Gross asset value 694   694  
Accumulated Amortization (347)   (347)  
Balance 347   347  
Human Antibodies Kadouche [Member]        
Intangible Assets [Line Items]        
Balance     381  
Amortization     (23)  
Impairment     (358)  
Balance 0   0  
Gross asset value 0   0  
Accumulated Amortization 0   0  
Balance 0   0  
Anti-ferritin Antibody Mablife [Member]        
Intangible Assets [Line Items]        
Balance     318  
Amortization     (23)  
Impairment     (295)  
Balance 0   0  
Gross asset value 0   0  
Accumulated Amortization 0   0  
Balance 0   0  
Ceplene Acquisition Intangibles [Member]        
Intangible Assets [Line Items]        
Balance     3,976  
Amortization     (461)  
Impairment     0  
Balance 3,515   3,515  
Gross asset value 4,310   4,310  
Accumulated Amortization (795)   (795)  
Balance $ 3,515   $ 3,515